PharmaCyte Biotech, Inc. (PMCB) DCF Valuation

PharmaCyte Biotech, Inc. (PMCB) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

PharmaCyte Biotech, Inc. (PMCB) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Discover the true potential of PharmaCyte Biotech, Inc. (PMCB) with our advanced DCF Calculator! Adjust essential assumptions, explore various scenarios, and evaluate how these changes affect the valuation of PharmaCyte Biotech, Inc. (PMCB) – all within a convenient Excel template.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020		 AY2
2021		 AY3
2022		 AY4
2023		 AY5
2024		 FY1
2025		 FY2
2026		 FY3
2027		 FY4
2028		 FY5
2029
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -3.8 .0 .0 .0 .0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation 3.8 3.6 4.4 6.5 .0 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -7.7 -3.6 -4.4 -6.5 .0 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash .9 2.2 85.4 68.0 50.2 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .2 .2 .2 .1 .4 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -7.7 -3.6 -4.2 -6.5 .0 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -3.6 .0 .2 -.1 .3 -.4 .0 .0 .0 .0
WACC, % 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39 5.39
PV UFCF
SUM PV UFCF -.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 0
Net Debt -50
Equity Value 50
Diluted Shares Outstanding, MM 10
Equity Value Per Share 5.20

What You Will Get

  • Comprehensive Financial Model: PharmaCyte Biotech’s actual data supports accurate DCF valuation.
  • Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential parameters.
  • Real-Time Calculations: Automatic updates ensure you receive immediate feedback as you adjust inputs.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
  • Flexible and Reusable: Designed for adaptability, allowing for repeated application in detailed forecasting.

Key Features

  • Customizable Clinical Trial Parameters: Adjust vital inputs such as patient enrollment rates, treatment efficacy, and trial duration.
  • Instant DCF Valuation: Quickly computes intrinsic value, NPV, and various financial metrics.
  • High-Precision Accuracy: Incorporates PharmaCyte's actual financial data for precise valuation results.
  • Effortless Scenario Analysis: Evaluate different clinical outcomes and strategies with ease.
  • Efficiency Booster: Streamline the process of developing intricate valuation models without starting from scratch.

How It Works

  • Step 1: Download the prebuilt Excel template featuring PharmaCyte Biotech, Inc.'s (PMCB) data.
  • Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
  • Step 3: Update your forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly see the recalculated results, including PharmaCyte Biotech, Inc.'s (PMCB) intrinsic value.
  • Step 5: Utilize the outputs to make informed investment decisions or create reports.

Why Choose This Calculator for PharmaCyte Biotech, Inc. (PMCB)?

  • User-Friendly Interface: Tailored for both newcomers and seasoned professionals.
  • Customizable Inputs: Adjust parameters effortlessly to suit your financial analysis.
  • Real-Time Valuation: Monitor immediate updates to PharmaCyte’s valuation as you tweak inputs.
  • Preloaded Financial Data: Comes with PharmaCyte’s actual financial metrics for swift evaluations.
  • Relied Upon by Experts: Utilized by investors and analysts for strategic decision-making.

Who Should Use PharmaCyte Biotech, Inc. (PMCB)?

  • Investors: Gain insights into cutting-edge biotech innovations to make informed investment choices.
  • Biotech Analysts: Streamline your research with comprehensive data on PharmaCyte's pipeline and market potential.
  • Consultants: Easily tailor presentations and reports to highlight PharmaCyte's unique offerings.
  • Healthcare Enthusiasts: Expand your knowledge of biotechnology and its impact on patient care through real-life case studies.
  • Educators and Students: Utilize PharmaCyte's advancements as a case study in biotech and pharmaceutical courses.

What the Template Contains

  • Preloaded PMCB Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.

No products were found matching.